Atlas Trials

Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

Clinical trial NCT06620822 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06620822
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2024-09-30
Primary completion
2026-09-30
Enrollment
296

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.